Affiliation:
1. Memorial Health System, Pembroke Pines, FL 33024, USA
Abstract
Over the last decade, treatment paradigms for breast cancer have undergone a renaissance, particularly in hormone-receptor-positive/HER2-negative breast cancer. These revolutionary therapies are based on the selective targeting of aberrancies within the cell cycle. This shift towards targeted therapies has also changed the landscape of disease monitoring. In this article, we will review the fundamentals of cell cycle progression in the context of the new cyclin-dependent kinase inhibitors. In addition to discussing the currently approved cyclin-dependent kinase inhibitors for breast cancer, we will explore the ongoing development and search for predictive biomarkers and modalities to monitor treatment.
Reference48 articles.
1. (2023, September 01). U.S. Cancer Statistics Data Visualizations Tool|CDC, Available online: https://www.cdc.gov/cancer/uscs/dataviz/index.htm.
2. G1 Cell-Cycle Control and Cancer;Nature,2004
3. Overall Survival Results from the Randomized Phase 2 Study of Palbociclib in Combination with Letrozole versus Letrozole Alone for First-Line Treatment of ER+/HER2− Advanced Breast Cancer (PALOMA-1, TRIO-18);Finn;Breast Cancer Res. Treat.,2020
4. Palbociclib plus Letrozole as First-Line Therapy in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with Extended Follow-Up;Rugo;Breast Cancer Res. Treat.,2019
5. Fulvestrant plus Palbociclib versus Fulvestrant plus Placebo for Treatment of Hormone-Receptor-Positive, HER2-Negative Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy (PALOMA-3): Final Analysis of the Multicentre, Double-Blind, Phase 3 Randomised Controlled Trial;Cristofanilli;Lancet Oncol.,2016
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献